这些治疗方法表面上看是阻止SARS-CoV-2病毒复制和导致严重疾病。 Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill. EPA/PFIZER INC. Source: PFIZER INC. 澳大利亚副 ...

▎药明康德内容团队编辑今日，美国盖伦基金会（TheGalien Foundation）公布了素有“医药界的诺贝尔奖”之称的盖伦奖（PrixGalien USA ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Wednesday, the New England Journal of Medicine published full study data from the Phase 2/3 trial of Pfizer Inc’s (NYSE:PFE) Paxlovid (Nirmatrelvir in combination with ritonavir). They shared ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a US national stockpile delivery led to US$2.7 billion in sales for the drug, Pfizer said Tuesday (Oct 29).

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

Demand for the drugmaker’s Paxlovid treatment spurred by the latest COVID wave and a U.S. national stockpile delivery led to ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

Pfizer (PFE) reported its third-quarter earnings ... was primarily driven in part to sales from its COVID-19 treatment Paxlovid. The medication was the company’s best-selling drug in the third ...

It ultimately raked in billions of dollars in sales for the first approved COVID-19 vaccine. Pfizer also made a fortune with ...